Molecular Therapy

FIGURE 3

FROM:

2'-O-methyl-modified RNAs Act as TLR7 Antagonists

Marjorie Robbins, Adam Judge, Lisa Liang, Kevin McClintock, Ed Yaworski and Ian MacLachlan

BACK TO ARTICLE

Figure 3.

Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

2'-O-methyl (2'OMe) single-stranded RNA (ssRNA) inhibits loxoribine-mediated interferon-alpha (IFN-alpha)and interleukin-6 (IL-6) production in both human and murine systems in vitro. Cytokine responses from (a, b) human peripheral blood mononuclear cells or (c, d) murine Flt3L dendritic cells treated with the TLR7 agonist loxoribine at 300 mumol/l or 30 mumol/l, respectively. Cells were treated simultaneously with soluble loxoribine plus either medium alone, lipid vehicle (lipid), or lipid-formulated native ssRNA (GFP-S) or 2'OMe RNAs [Luc-mU or (mU)21] for 24 hours before secreted (a, c) IFN-alpha and (b, d) IL-6 were assayed. Control cultures received phosphate-buffered saline (PBS) vehicle only; RNA was added at 0.2 mumol/l (approx1.4 mug/ml) final concentration. Data reflect mean cytokine levels + SD of triplicate cultures and are representative of at least two independent experiments. GFP, green flourescent protein.

BACK TO ARTICLE